½ÃÀ庸°í¼­
»óǰÄÚµå
1505174

¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå(2024-2031³â)

Global Fluorescence Guided Surgery System Market 2024-2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Orion Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 140 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2031³â)¿¡ CAGR 15.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Çü±¤ °¡ÀÌµå ¼ö¼ú(FGS)Àº ¼ö¼ú Áß ºñ°¡½Ã±¤¼±À» »ç¿ëÇÏ¿© ¼ö¼ú ºÎÀ§ÀÇ ½Ç½Ã°£ À̹ÌÁö¸¦ ¸¸µå´Â ±¤ÇÐ À̹Ì¡ ±â¼úÀÔ´Ï´Ù. À̸¦ ÅëÇØ ¿Ü°úÀÇ»ç´Â Á¾¾ç, ¾Ï¼¼Æ÷, ½Å°æ°ú °°Àº ÇØºÎÇÐÀû Ư¡À» º¸´Ù Á¤È®Çϰí Á¤¹ÐÇÏ°Ô ½Äº°Çϰí Á¦°ÅÇϰųª ¿ÂÁ¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. FGS´Â ¶ÇÇÑ °Ç°­ÇÑ Á¶Á÷À» ¼Õ»ó½Ãų À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖÀ¸¹Ç·Î ¼ö¼ú ½Ã°£À» ´ÜÃàÇϰí Àç¼ö¼úÀÇ Çʿ伺À» ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¼ö¼ú °Ç¼ö Áõ°¡

¿Ü°ú ¼ö¼ú °Ç¼ö, °Ç°­ °ü¸® ÁöÃâ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎÀº ¸ðµÎ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ÀÌ´Â ¼¼°è FGS ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÕ´Ï´Ù. ¾Ç¼º ¼¼Æ÷¿Í Ç¥Àû Á¶Á÷¿¡ ¸Å¿ì ¼±ÅÃÀûÀÎ °³·®Çü Çü±¤ ÇÁ·Îºê´Â ¿¬±¸ °³¹ßÀÇ ¼º°úÀÔ´Ï´Ù. ¼ö¼ú Áß ÀÌ·¯ÇÑ ÇÁ·Îºê´Â Àǻ簡 ¼ö¼ú ºÎÀ§¸¦ ´õ ¼±¸íÇÏ°Ô º¼ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. FGS°¡ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â °ÍÀ¸·Î ÀÓ»óÀûÀ¸·Î ÀÔÁõµÇ¾ú±â ¶§¹®¿¡ ÀÇ·á ½Ã¼³Àº ¼ö¼ú Áß¿¡ FGS¸¦ µµÀÔÇÒ ÀÇ¿åÀ» ³ôÀÔ´Ï´Ù.

Áõ°¡ÇÏ´Â ¿¬±¸°³¹ß ¼ö

¿¬±¸°³¹ß Ȱµ¿ÀÇ °á°ú, ¾Ç¼º ¼¼Æ÷ ¹× ±âŸ Ç¥Àû Á¶Á÷¿¡ ¸Å¿ì ¼±ÅÃÀûÀÎ º¸´Ù Áøº¸µÈ Çü±¤ ÇÁ·Îºê°¡ »ý¼ºµÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ÇÁ·Îºê¸¦ »ç¿ëÇϸé Àǻ簡 ¼ö¼ú ºÎÀ§¸¦ º¸´Ù ¼±¸íÇÏ°Ô º¸¸é¼­ ¼ö¼úÀ» ¼öÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. È®´ëÇÏ´Â ÀÓ»ó µ¥ÀÌÅÍ ¼öÁýÀº FGS°¡ ȯÀÚ °á°ú¸¦ °³¼±ÇßÀ½À» º¸¿©ÁÝ´Ï´Ù. ÀÇ·á½Ã¼³¿¡ ÀÇÇÑ ÀÌ·¯ÇÑ ±â¼úÀÇ »ç¿ëÀº ÀÌ·¯ÇÑ Áö½Ä¿¡ µÞ¹ÞħµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

SPY ½Ã½ºÅÛÀÌ ÃÖ´ë ºÎ¹®¿Í ¿¹Ãø

½ÉÀåÁúȯÀÇ À¯º´·üÀÌ ³ô¾ÆÁü¿¡ µû¶ó ¼ö¼ú ¼ºÀûÀ» Çâ»ó½Ã۱â À§ÇØ FGS¸¦ ä¿ëÇÑ SPY ½Ã½ºÅÛÀÌ ½ÃÀåÀ» ¼®±ÇÇϰí ÀÖ½À´Ï´Ù. SPY ½Ã½ºÅÛ°ú ¸¶Âù°¡Áö·Î FGS ½Ã½ºÅÛÀº ¼ö¼ú Áß¿¡ ƯÁ¤ »ý¹°ÇÐÀû Ÿ°Ù°ú ½Ç½Ã°£ Á¶Á÷ °ü·ù ¸ð´ÏÅ͸µÀ» Ȱ¿ëÇÕ´Ï´Ù. SPY ½Ã½ºÅÛÀ» ÅëÇØ ¿Ü°úÀÇ»ç´Â ÃÖ¼ÒÇÑÀÇ ¾î·Á¿òÀ¸·Î ¼ö¼úÀ» ¼öÇàÇϰí ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ¼¼°è ½ÃÀå¿¡¼­ Å« Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù.

Áö¿ªº° Àü¸Á

¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù), À¯·´(¿µ±¹, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, µ¶ÀÏ, ÇÁ¶û½º ¹× ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Àεµ, Áß±¹, ÀϺ», Çѱ¹, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ¼¼°è ±âŸ Áö¿ª(Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¶óƾ¾Æ¸Þ¸®Ä«)À» Æ÷ÇÔÇÑ Áö¿ªº°·Î ´õ¿í ¼¼ºÐÈ­µÇ¾î ÀÖ½À´Ï´Ù.

ÀÓ»ó ¿¬±¸ ±âÁö·Î¼­ ¾Æ½Ã¾ÆÅÂÆò¾ç ±¹°¡

  • ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àӻ󿬱¸¿Í FGSÀÇ °øµ¿¿¬±¸ÀÇ Áß½ÉÁö·Î¼­ ±â¼ú °³¹ß°ú ÀÓ»ó½ÃÇèÀ» ½Ç½ÃÇϱâ À§ÇØ Çмú±â°ü°ú ÀÇ·áÁ¦°ø¾÷ü°¡ ¸ð¿© ÀÖ½À´Ï´Ù.
  • Çü±¤ °¡À̵å Çϼö±âÀÇ »óȯ¿¡ °üÇÑ ±ÔÁ¦¿Í Á¤Ã¥Àº Áö¿ª¿¡ µû¶ó ƯÁ¤ ¾ÖÇø®ÄÉÀÌ¼Ç ¹× ÀÇ·á Á¦°ø¾÷ü¿¡ µû¶ó ´Ù¸¨´Ï´Ù.

ºÏ¹Ì°¡ ÁÖ¿ä ½ÃÀå Á¡À¯À²À» Â÷Áö

¾ÏÀ̳ª ½ÉÇ÷°ü ÁúȯÀ» Æ÷ÇÔÇÑ ¸¸¼º ÁúȯÀÇ ³ôÀº À¯º´·ü, °íµµÀÇ ¼ö¼ú Ä¡·á¿¡ ´ëÇÑ ³ôÀº ÀÇ½Ä ¹× ³ôÀº ¼ö¿ä°¡ ÀÌ Áö¿ª ½ÃÀå Á¡À¯À²¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ °í±Þ ÀÇ·á ÀÎÇÁ¶ó¿Í ¼ö¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ ÀÇ·á »óȯ Á¤Ã¥Àº ÀÌ Áö¿ª ½ÃÀå ¼ºÀåÀ» À̲ø°í ÀÖ½À´Ï´Ù.

¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå¿¡ ÁøÃâÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â Hamamatsu Photonics K.K., Olympus Corp., Stryker Corp., Medtronic PLC, Getinge AB µîÀÌ ÀÖ½À´Ï´Ù. ½ÃÀå °æÀï·ÂÀ» À¯ÁöÇϱâ À§ÇØ °¢ ȸ»ç´Â Á¦ÈÞ, ÇÕº´, Àμö µîÀÇ Àü·«À» Àû¿ëÇÏ¿© »ç¾÷ È®´ë ¹× Á¦Ç° °³Ã´¿¡ Á¡Á¡ ÈûÀ» ½ñ°í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ °³¿ä

  • ¾÷°èÀÇ ÇöȲ ºÐ¼® ¹× ¼ºÀå ÀáÀç·ÂÀÇ Àü¸Á
  • Á¶»ç ¹æ¹ý ¹× µµ±¸
  • ½ÃÀå ºÐ¼®
    • ºÎ¹®º°
    • Áö¿ªº°

Á¦2Àå ½ÃÀå °³¿ä ¹× ÀλçÀÌÆ®

  • Á¶»ç ¹üÀ§
  • ¾Ö³Î¸®½ºÆ®ÀÇ ÀλçÀÌÆ® ¹× ÇöÀç ½ÃÀå µ¿Çâ
    • ÁÖ¿ä ¾÷°è µ¿Çâ
    • ½ÃÀå Ãßõ »çÇ×
    • °á·Ð

Á¦3Àå °æÀï ±¸µµ

  • ÁÖ¿ä ±â¾÷ ºÐ¼®
  • Hamamatsu Photonics KK
    • °³¿ä
    • À繫 ºÐ¼®
    • SWOT ºÐ¼®
    • ÃÖ±Ù µ¿Çâ
  • Olympus Corp.
    • ±â¾÷ °³¿ä
    • À繫 ºÐ¼®
    • SWOT ºÐ¼®
    • ÃÖ±Ù µ¿Çâ
  • Stryker Corp.
    • °³¿ä
    • À繫 ºÐ¼®
    • SWOT ºÐ¼®
    • ÃÖ±Ù µ¿Çâ
  • ÁÖ¿ä Àü·« ºÐ¼®

Á¦4Àå ½ÃÀå ¼¼ºÐÈ­

  • ¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå : À¯Çüº°
    • SPY ½Ã½ºÅÛ
    • PDE ½Ã½ºÅÛ
    • VS3 À̸®µã ½Ã½ºÅÛ
  • ¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå : ¼ö¼úº°
    • °³º¹ ¼ö¼ú
    • º¹°­°æ ¹× ³»½Ã°æ
  • ¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå : ¿ëµµº°
    • ¾Ï ¼ö¼ú
    • ½ÉÀåÇ÷°ü ¼ö¼ú
    • ±âŸ(¼ÒÈ­±â ¿Ü°ú)

Á¦5Àå Áö¿ªº° ºÐ¼®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ÇÁ¶û½º
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¼¼°è ±âŸ Áö¿ª
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦6Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • 3M Company
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company(BD)
  • Boston Scientific Corp.
  • CONMED Corp.
  • Curadel LLC
  • Erbe Elektromedizin Gmbh
  • Getinge AB
  • Irillic Pvt. Ltd.
  • Johnson & Johnson Service, Inc.
  • Karl Storz SE & Co. KG
  • Medtronic PLC
  • OnLume Inc.
  • PerkinElmer, Inc.
  • Shimadzu Corp.
AJY 24.07.11

Fluorescence Guided Surgery System Market Size, Share & Trends Analysis Report by Type (SPY System, PDE System, and VS3 Iridium Systems), by Surgery (Open Surgery, and Laparoscopy/Endoscopy), and by Application (Cancer Surgeries, Cardiovascular Surgeries, and Others) Forecast Period (2024-2031)

Fluorescence-guided surgery system market is anticipated to grow at a CAGR of 15.7% during the forecast period (2024-2031). Fluorescence-guided surgery (FGS) is an optical imaging technique that uses invisible light to create a real-time image of the surgical area during a procedure. This helps surgeons identify and remove or preserve anatomical features like tumors, cancer cells, and nerves with greater precision and accuracy. FGS can also reduce the risk of damaging healthy tissue, which can shorten the operation and decrease the need for repeat surgeries.

Market Dynamics

A growing number of surgeries

The number of surgical procedures, healthcare spending, and regulatory approvals are all expected to increase, which will drive growth in the global FGS system market. Improved fluorescent probes that are extremely selective to malignant cells or target tissues are the result of research and development. During operations, these probes help doctors see the surgical site more clearly. Clinical evidence demonstrates that FGS improves patient outcomes, which motivates medical facilities to implement it during surgeries.

A rising number of research and development

Research and development activities result in the creation of ever-more-advanced fluorescent probes that are extremely selective to malignant cells or other target tissues. With the use of these probes, doctors can see the surgical site more clearly while performing their procedures. An expanding clinical data collection shows that FGS has improved patient outcomes. The use of these technologies by healthcare facilities is encouraged by these findings.

Market Segmentation

  • Based on type, the market is sub-segmented into SPY system, PDE system, and VS3 iridium system.
  • Based on surgery, the market is bifurcated into open surgery and laparoscopy/endoscopy.
  • Based on application, the market is segmented into cancer surgeries, cardiovascular surgeries, and others (gastrointestinal).

SPY System is Projected to Emerge as the Largest Segment

The growing prevalence of cardiac problems has led to a dominant market for the SPY system, which employs FGS to enhance surgical outcomes. Similar to the SPY system, FGS systems leverage particular biological targets and real-time tissue perfusion monitoring during surgery. With the SPY system, surgeons can perform procedures with minimal difficulties and improve patient outcomes. Hence, these systems hold a major share in the global market.

Regional Outlook

The global fluorescence-guided surgery system market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Asia-Pacific countries to serve as a clinical research center

  • The Asia-Pacific region serves as a center for clinical research and FGS collaboration, bringing together academic institutions and medical providers to conduct technology development and clinical trials.
  • Policies and regulations regarding reimbursement for fluorescence-guided procedures differ based on the particular application and healthcare provider across the region.

North America Holds Major Market Share

The high prevalence of chronic diseases including cancer and cardiovascular disease, as well as the high level of awareness and demand for sophisticated surgical treatments across the region, are the key contributors to the regional market share. Moreover, the advanced healthcare infrastructure of the region along with favorable medical reimbursement policies regarding surgical procedures are likely to drive the regional market growth.

The major companies serving the global fluorescence-guided surgery system market include Hamamatsu Photonics K.K., Olympus Corp., Stryker Corp., Medtronic PLC, and Getinge AB, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Industry Trends
    • 2.2.2. Market Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Hamamatsu Photonics K.K.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Olympus Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Stryker Corp.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Fluorescence Guided Surgery System Market by Type
    • 4.1.1. SPY System
    • 4.1.2. PDE System
    • 4.1.3. VS3 Iridium System
  • 4.2. Global Fluorescence Guided Surgery System Market by Surgery
    • 4.2.1. Open Surgery
    • 4.2.2. Laparoscopy/Endoscopy
  • 4.3. Global Fluorescence Guided Surgery System Market by Application
    • 4.3.1. Cancer Surgeries
    • 4.3.2. Cardiovascular Surgeries
    • 4.3.3. Others (Gastrointestinal Surgery)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. 3M Company
  • 6.2. B. Braun Melsungen AG
  • 6.3. Becton, Dickinson and Company (BD)
  • 6.4. Boston Scientific Corp.
  • 6.5. CONMED Corp.
  • 6.6. Curadel LLC
  • 6.7. Erbe Elektromedizin Gmbh
  • 6.8. Getinge AB
  • 6.9. Irillic Pvt. Ltd.
  • 6.10. Johnson & Johnson Service, Inc.
  • 6.11. Karl Storz SE & Co. KG
  • 6.12. Medtronic PLC
  • 6.13. OnLume Inc.
  • 6.14. PerkinElmer, Inc.
  • 6.15. Shimadzu Corp.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦